Read on Twitter
Another publication of phase 2 results from the Oxford/AstraZeneca vaccine trial in the UK. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext And it's as complicated as you'd expect of a chunk of reporting from a phase 2/3 trial that had grown to <checks notes> 28 arms by October.
OK, I think the big news from the Oxford/AstraZeneca Lancet publication isn't the phase 2 results: it's in the appendix - the protocol of the UK phase 2/3 trial & it upends what's in the protocol they released for their US trial...1/n https://www.thelancet.com/cms/10.1016/S0140-6736(20)32466-1/attachment/1246f6f0-bef8-4428-b9d1-cf9aaced64bd/mmc1.pdf
...Protocol for US trial was pretty standard: interim analysis at 75 events. But in this new one, they say they're going to pool results from studies of different phases, different sizes & going to regulators with that, without the US trial (which has a placebo comparator)... 2/n
... So instead of having a trial with enough power to answer the question at a set level, they'll be doing meta-analysis 
This is going to be.... challenging. /fin
This is going to be.... challenging. /fin
... PS. I said it upends what's in the protocol for the US trial, but that's the wrong word. It's the expectations that came from that protocol that are upended. It remains what it was, but they're clearly not expecting a result to come from it soon.
